# BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly owned subsidiary HOPE Therapeutics Inc., announced that Founder, Chairman, and CEO Dr. Jonathan Javitt will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on Oct. 8, 2025, at 9:30 a.m. ET. Dr. Javitt will discuss the upcoming launch of a low-dose D-Cycloserine (DCS) product shown to enhance the effectiveness of Transcranial Magnetic Stimulation (TMS) for depression, as well as the Company’s expanded clinical operations in Florida and collaborations with the U.S. Department of Veterans Affairs to treat veterans with suicidal depression and PTSD.

 To view the full press release, visit https://ibn.fm/KRCWz

 About NRx Pharmaceuticals, Inc.

 NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression.

 NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-nrx-pharmaceuticals-inc-nasdaq-nrxp-to-present-at-noble-capital-markets-emerging-growth-virtual-equity-conference/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nrx-pharma-to-present-depression-breakthrough-at-noble-capital-conference/f6602ddfea223ccb0e37f87400b523c0) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2510/6/divenLiH.webp)